NovoCure stock is coming off a very difficult five year stretch, with the share price down about 90%, yet the latest valuation checks still lean toward the shares looking cheap on several measures. That contrast, alongside fresh company developments in cancer therapies, is what investors are weighing now.

• Over the past five years, NovoCure shares have declined about 90%. As a result, any sign of a sustainable business recovery can have an outsized impact on how the market prices the stock.
• Recent commercial progress for its Tumor Treating Fields therapies can support expectations for stronger cash generation, while an active legal investigation tied to a clinical trial outcome may weigh on risk perceptions.
• NovoCure screens as undervalued on most of Simply Wall St's checks, with a high value score of 5 out of 6. This suggests the broader set of valuation metrics leans cheap rather than expensive.

For investors, the debate is whether NovoCure's weak long term share performance and current risks are already reflected in the price or if the recent progress still leaves room for upside before the valuation looks full.

Is NovoCure a Bargain on Sales?

P/S is a sensible check for NovoCure because revenue is the clearest financial anchor while the company is still reporting losses. On this measure, NovoCure currently trades on a P/S of about 2.5x.

That sits a little below the Medical Equipment industry average of around 2.8x and well below the peer group average of roughly 10.0x. Simply Wall St's fair P/S ratio for NovoCure is about 5.0x, which is higher than where the stock trades now. This indicates that, given the company’s mix of growth profile, margins, size and risks, the present multiple is below what the model would expect.

Despite recent revenue headlines around record quarterly sales and a higher full year outlook, NovoCure still trades at a discount to that fair P/S level and to many peers that carry materially higher sales multiples.

On the P/S multiple, NovoCure stock currently appears undervalued compared with both its tailored fair ratio and many peers.

The NovoCure Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for NovoCure pick up where the valuation puzzle leaves off and explain which combinations of future growth, margins and earnings would need to occur for the stock to be worth significantly more or less than it is today. Each narrative links its outcome to a specific view on how NovoCure's growth, profitability and risks could evolve. You can revisit these narratives as fresh information comes through on the Community page.

One of the top community narratives on NovoCure: 69% undervalued

"NovoCure's pioneering position in device-based, non-invasive therapy uniquely aligns with the increasing global demand for alternatives to chemotherapy and radiation, and as aging populations dramatically increase cancer incidence..."

Do you think there's more to the story for NovoCure? Head over to our Community to see what others are saying!

The Bottom Line

NovoCure screens as undervalued on market multiples, which means the current price already bakes in a fair amount of caution around its business risks and loss making status. For you as an investor, the key question is whether that discount compensates for the uncertainties flagged earlier, including legal and clinical trial related risks. The main point of the bull versus bear debate is whether NovoCure can translate its Tumor Treating Fields progress into durable revenue and clearer profitability, which could support a higher multiple, or whether the current valuation simply reflects the ongoing execution and risk profile.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.